2025-12-03 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co Inc. (MRK) based on the provided data.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Merck & Co Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare products.
*   **Return Rate:** MRK's cumulative return (19.10%) significantly underperforms the S&P 500 (VOO) (100.36%).
*   **Divergence:** The divergence of -78.1 indicates a substantial gap in performance between MRK and the S&P 500, with a relative divergence of 20.4 suggesting it is near the minimum level, compared to historic divergences.

*   **Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
|------------|---------|--------|---------|--------|--------|
| 2015-2017  | 1.0%    | 68.5%  | -28.0%  | 0.0    | 134.1  |
| 2016-2018  | 36.0%   | 69.8%  | 21.0%   | -0.0   | 182.1  |
| 2017-2019  | 40.0%   | 69.8%  | 18.0%   | 0.3    | 216.8  |
| 2018-2020  | 16.0%   | 79.6%  | -8.0%   | 0.3    | 194.9  |
| 2019-2021  | 2.0%    | 79.6%  | -44.0%  | 0.7    | 191.4  |
| 2020-2022  | 15.0%   | 79.6%  | 16.0%   | 0.7    | 277.1  |
| 2021-2023  | 33.0%   | 79.6%  | 31.0%   | 0.3    | 272.3  |
| 2022-2024  | -4.0%   | 79.6%  | -25.0%  | 0.2    | 248.5  |
| 2023-2025  | -30.0%  | 71.5%  | -95.0%  | 1.8    | 252.1  |

**Analysis:**

*   **CAGR Variation:** The Compounded Annual Growth Rate (CAGR) fluctuates significantly, ranging from -30.0% to 40.0% over different three-year periods.  This indicates volatility in MRK's performance. The most recent period (2023-2025) shows a concerning decline.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, hovering around 70-80%, indicating significant potential for losses during downturns.
*   **Alpha:** Alpha, which represents the excess return compared to the benchmark, is largely negative, especially in recent periods. The period from 2023-2025 is particularly concerning, with Alpha at -95.0%. This suggests MRK has significantly underperformed relative to its risk (Beta).
*   **Beta:** Beta fluctuates but trends upward.  A higher beta means the stock is more volatile than the market. The most recent beta of 1.8 from 2023-2025 indicates high volatility relative to the market during that period.
*   **Cap(B):** The company's market capitalization has fluctuated.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 100.92
*   **Last Market Data:** Price: 100.89, Previous Close: 101.83, Change: -0.92
*   **Moving Averages:**
    *   5-day SMA: 103.288
    *   20-day SMA: 93.5907
    *   60-day SMA: 87.6016

**Analysis:**

*   The current price is slightly below the previous close, indicating a minor recent dip.
*   The 5-day SMA is above the current price, indicating the price has recently decreased.
*   The 20-day SMA is below the 5-day SMA, implying that the stock might be stabilizing after recent price increases.
*   The 60-day SMA is below both the 20-day and 5-day SMAs, suggesting a longer-term upward trend, although the shorter-term trends show recent weakening.

**3) RSI, PPO, and Market Risk Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (Medium to High Investment Recommended)
*   **RSI:** 76.13 (Overbought)
*   **PPO:** 0.99
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (10 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** 1.9 (+) (Short-term Increase)
*   **Expected Return:** -36.4% (Long-term underperformance vs. S&P 500)

**Analysis:**

*   The MRI suggests a medium to high level of investment suitability.
*   The RSI is above 70, indicating that the stock may be overbought and a correction is possible.
*   The PPO value doesn't provide as much clarity without historical context, but it indicates the relationship between two moving averages.
*   The Hybrid Signal suggests a bullish stance, recommending full investment, likely based on the MRI and other factors, but must be considered in contrast with the negative expected return.
*   The recent increase in relative divergence suggests a short-term positive trend.
*   The negative expected return is a significant concern, indicating that long-term investment at the current price might lead to underperformance compared to the S&P 500.

**4) Recent News & Significant Events**

*   **Positive News:** Several news articles highlight positive developments, including a surprise win (presumably in a clinical trial), reasons for a stock surge, and an increased price target from Goldman Sachs ($120). The dividend increase is also positive.
*   **Negative News:** One article reports a stock price decrease of 2.9% and identifies a potential reason.

**Analysis:**

*   Recent news paints a mixed picture. While positive catalysts like a clinical trial win and dividend increase are present, the price target adjustments and price drop suggest volatility and uncertainty.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.97 (Buy)
*   **Number of Opinions:** 26
*   **Target Price:** Average: 105.35, High: 139.00, Low: 82.00

**Analysis:**

*   Analysts, on average, have a "Buy" rating for MRK.
*   The average target price suggests a potential upside from the current price. However, the wide range between the high and low target prices indicates uncertainty among analysts.

**5) Recent Earnings Analysis**

| 날짜         | EPS   | 매출      |
|--------------|-------|-----------|
| 2025-11-05   | 2.32  | 17.28 B$  |
| 2025-08-05   | 1.76  | 15.81 B$  |
| 2025-05-02   | 2.01  | 15.53 B$  |
| 2024-11-06   | 1.25  | 16.66 B$  |
| 2025-11-05   | 1.25  | 16.66 B$  |

**Analysis:**

*   The most recent EPS (2.32) and Revenue (17.28B$) are the highest in the provided data.
*   EPS and Revenue have generally been increasing over the last few quarters, indicating positive growth momentum.

**6) Financial Information**

*   **Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $17.28B   | 77.69%        |
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |

*   **Capital and Profitability:**

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-09-30 | $51.85B   | 11.16% |
| 2025-06-30 | $48.99B   | 9.04%  |
| 2025-03-31 | $48.34B   | 10.51% |
| 2024-12-31 | $46.31B   | 8.08%  |
| 2024-09-30 | $44.50B   | 7.09%  |

**Analysis:**

*   **Revenue and Profit Margin:** Revenue has been generally increasing, with the most recent quarter showing the highest value. Profit margins are exceptionally high and relatively stable, indicating strong profitability.
*   **Equity and ROE:** Equity has consistently grown, indicating a strengthening financial position. ROE (Return on Equity) has also generally increased, reflecting improved profitability relative to shareholder equity.

**7) Comprehensive Analysis (Summary)**

**Overall Assessment:**

Merck & Co Inc. (MRK) presents a mixed investment picture:

*   **Positives:**
    *   Strong recent earnings and revenue growth.
    *   Very high and stable profit margins.
    *   Growing equity and improving ROE.
    *   Positive analyst consensus with a "Buy" rating.
    *   Recent positive news catalysts.
    *   Relatively High MRI score.

*   **Negatives:**
    *   Significant underperformance compared to the S&P 500.
    *   High Maximum Drawdown, indicating significant risk.
    *   Negative expected return compared to the S&P 500 (long term).
    *   RSI indicating overbought conditions which implies it may be poised for correction.
    *   The significant negative alpha values recently indicate the stock is underperforming the market, after adjusting for risk.
    *   High recent Beta of 1.8 implies it is much more volatile compared to the market.

**Investment Recommendation:**

The investment decision is complex.

*   **Bullish Scenario:** If you believe in the continued success of MRK's pipeline, ability to maintain high margins, and outperformance of the analyst target prices, a **cautious buy** might be considered, especially if the price dips from its overbought state.
*   **Bearish Scenario:** Given the underperformance compared to the S&P 500, high risk (MDD), and negative long-term expected return, investors looking for broad market exposure should **avoid** MRK or significantly underweight it in their portfolio.
*   **Neutral Scenario:** If invested, hold existing positions, but consider rebalancing to reduce exposure if the stock rises significantly.

**Important Considerations:**

*   **Risk Tolerance:** The high MDD makes MRK unsuitable for risk-averse investors.
*   **Time Horizon:** The negative expected return suggests a long-term investment may underperform the market.
*   **Diversification:** If investing in MRK, ensure proper diversification across your portfolio to mitigate risk.
*   **Further Research:** Thoroughly investigate the company's pipeline, competitive landscape, and future growth prospects before making any investment decision.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.